These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 33660034)

  • 1. Whole-body low-dose computed tomography (WBLDCT) in staging and re-staging of multiple myeloma.
    Ippolito D; Giandola T; Maino C; Pecorelli A; Ragusi M; Porta M; Gandola D; Franzesi CT; Sironi S
    Ann Hematol; 2021 May; 100(5):1241-1249. PubMed ID: 33660034
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Accuracy of whole-body low-dose multidetector CT (WBLDCT) versus skeletal survey in the detection of myelomatous lesions, and correlation of disease distribution with whole-body MRI (WBMRI).
    Gleeson TG; Moriarty J; Shortt CP; Gleeson JP; Fitzpatrick P; Byrne B; McHugh J; O'Connell M; O'Gorman P; Eustace SJ
    Skeletal Radiol; 2009 Mar; 38(3):225-36. PubMed ID: 19009290
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Diagnostic value of whole-body low-dose computed tomography (WBLDCT) in bone lesions detection in patients with multiple myeloma (MM).
    Ippolito D; Besostri V; Bonaffini PA; Rossini F; Di Lelio A; Sironi S
    Eur J Radiol; 2013 Dec; 82(12):2322-7. PubMed ID: 24074647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A prospective study of Skeletal survey versus Low-dose whole-body CT for Osteolytic lesions in Multiple Myeloma.
    Gundesen MT; Asmussen JT; Haukås E; Schubert M; Abildgaard N; Schjesvold F; Lund T
    Eur J Haematol; 2022 May; 108(5):423-429. PubMed ID: 35113466
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Whole-body ultra-low dose CT using spectral shaping for detection of osteolytic lesion in multiple myeloma.
    Suntharalingam S; Mikat C; Wetter A; Guberina N; Salem A; Heil P; Forsting M; Nassenstein K
    Eur Radiol; 2018 Jun; 28(6):2273-2280. PubMed ID: 29322333
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simplified response monitoring criteria for multiple myeloma in patients undergoing therapy with novel agents using computed tomography.
    Schabel C; Horger M; Kum S; Weisel K; Fritz J; Ioanoviciu SD; Bier G
    Eur J Radiol; 2016 Dec; 85(12):2195-2199. PubMed ID: 27842666
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inter-observer agreement for the evaluation of bone involvement on Whole Body Low Dose Computed Tomography (WBLDCT) in Multiple Myeloma (MM).
    Zacchino M; Bonaffini PA; Corso A; Minetti V; Nasatti A; Tinelli C; Dore R; Calliada F; Sironi S
    Eur Radiol; 2015 Nov; 25(11):3382-9. PubMed ID: 25987427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Organ dose and total effective dose of whole-body CT in multiple myeloma patients.
    Hemke R; Yang K; Husseini J; Bredella MA; Simeone FJ
    Skeletal Radiol; 2020 Apr; 49(4):549-554. PubMed ID: 31612246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Whole Body Low Dose Computed Tomography (WBLDCT) Can Be Comparable to Whole-Body Magnetic Resonance Imaging (WBMRI) in the Assessment of Multiple Myeloma.
    Ippolito D; Giandola T; Maino C; Gandola D; Ragusi M; Bonaffini PA; Sironi S
    Diagnostics (Basel); 2021 May; 11(5):. PubMed ID: 34064594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnostic value of whole-body ultra-low dose computed tomography in comparison with spinal magnetic resonance imaging in the assessment of disease in multiple myeloma.
    Ippolito D; Talei Franzesi C; Spiga S; Besostri V; Pezzati S; Rossini F; Sironi S
    Br J Haematol; 2017 May; 177(3):395-403. PubMed ID: 28233900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Implemented myeloma management with whole-body low-dose CT scan: a real life experience.
    Mangiacavalli S; Pezzatti S; Rossini F; Doni E; Cocito F; Bolis S; Corso A
    Leuk Lymphoma; 2016 Jul; 57(7):1539-45. PubMed ID: 26788613
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Whole-body low-dose multidetector row-CT in the diagnosis of multiple myeloma: an alternative to conventional radiography.
    Horger M; Claussen CD; Bross-Bach U; Vonthein R; Trabold T; Heuschmid M; Pfannenberg C
    Eur J Radiol; 2005 May; 54(2):289-97. PubMed ID: 15837412
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Whole-Body Low-Dose CT in Multiple Myeloma: Diagnostic Value of Appendicular Medullary Patterns of Attenuation.
    Koutoulidis V; Terpos E; Klapa I; Cheliotis G; Ntanasis-Stathopoulos I; Boultadaki A; Gavriatopoulou M; Kastritis E; Dimopoulos MA; Moulopoulos LA
    AJR Am J Roentgenol; 2021 Mar; 216(3):742-751. PubMed ID: 33439048
    [No Abstract]   [Full Text] [Related]  

  • 14. Can whole-body low-dose multidetector CT exclude the presence of myeloma bone disease in patients with monoclonal gammopathy of undetermined significance (MGUS)?
    Spira D; Weisel K; Brodoefel H; Schulze M; Kaufmann S; Horger M
    Acad Radiol; 2012 Jan; 19(1):89-94. PubMed ID: 22142681
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of whole-body 64-slice multidetector computed tomography and conventional radiography in staging of multiple myeloma.
    Kröpil P; Fenk R; Fritz LB; Blondin D; Kobbe G; Mödder U; Cohnen M
    Eur Radiol; 2008 Jan; 18(1):51-8. PubMed ID: 17924119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Whole-body magnetic resonance imaging (WBMRI) versus whole-body computed tomography (WBCT) for myeloma imaging and staging.
    Treitl KM; Ricke J; Baur-Melnyk A
    Skeletal Radiol; 2022 Jan; 51(1):43-58. PubMed ID: 34031705
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Imaging in multiple myeloma: How? When?
    Zamagni E; Tacchetti P; Cavo M
    Blood; 2019 Feb; 133(7):644-651. PubMed ID: 30587527
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recommendations for acquisition, interpretation and reporting of whole body low dose CT in patients with multiple myeloma and other plasma cell disorders: a report of the IMWG Bone Working Group.
    Moulopoulos LA; Koutoulidis V; Hillengass J; Zamagni E; Aquerreta JD; Roche CL; Lentzsch S; Moreau P; Cavo M; Miguel JS; Dimopoulos MA; Rajkumar SV; Durie BGM; Terpos E; Delorme S
    Blood Cancer J; 2018 Oct; 8(10):95. PubMed ID: 30287814
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Whole-body low-dose computed tomography in multiple myeloma staging: Superior diagnostic performance in the detection of bone lesions, vertebral compression fractures, rib fractures and extraskeletal findings compared to radiography with similar radiation exposure.
    Lambert L; Ourednicek P; Meckova Z; Gavelli G; Straub J; Spicka I
    Oncol Lett; 2017 Apr; 13(4):2490-2494. PubMed ID: 28454425
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The benefit of using whole-body, low-dose, nonenhanced, multidetector computed tomography for follow-up and therapy response monitoring in patients with multiple myeloma.
    Horger M; Kanz L; Denecke B; Vonthein R; Pereira P; Claussen CD; Driessen C
    Cancer; 2007 Apr; 109(8):1617-26. PubMed ID: 17330855
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.